Evolution towards hormone independence of the MXT mouse mammarytumor is associated with a gradual change in its estrogen receptormolecular polymorphism

Cancer Biochemistry Biophysics

Volumn 16, Issue 1, 1997, Pages 169-182

  Piccart, Martine J ^a   Trivedi, Sunil ^a   Maaroufi, Younes ^a   Debbaudt, Ann ^a   Veenstra, Stéphane ^a   Leclercq, Guy ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL NUCLEUS; CHEMISTRY; CYTOSOL; EXPERIMENTAL NEOPLASM; FEMALE; GENETIC POLYMORPHISM; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; SERODIAGNOSIS; UTERUS;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL NUCLEUS; CYTOSOL; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; POLYMORPHISM, GENETIC; PRECIPITIN TESTS; RECEPTORS, ESTROGEN; UTERUS;

EID: 0032082851     PISSN: 03057232     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Castles C., S. A. W. Fuqua, D. M. Klotz and S. M. Hill (1993). Expression of a constitutively active estrogen receptor variant in the estrogen receptor negative BT-20 human breast cancer cell line. Cancer Res., 53, 5934.
2. Castoria G., A. Migliaccio, S. Green. M. Di Domenico, P. Chambon and F. Auricchio (1993). Properties of a purified estradiol-dependent calf uterus tyrosine kinase. Biochemisiry, 32, 1740.
3. Cavaillès V., S. Dauvois, P. S. Danielian and M. G. Parker (1994). Interaction of proteins with transcriptionally active estrogen receptors. Proc. Natl. Acad. Sci. USA. 91, 10009.
4. Cavaillès V., S. Dauvois, F. L'Horset, G. Lopez, S. Hoare, P. J. Kushner and M. G. Parker (1995). Nuclear factor RIP 140 modulates transcriptional activation by the estrogen receptor. EMBO J., 14, 3741.
5. Danguy A., R. Kiss, G. Leclercq, J C. Heuson and J. L. Pasteels (1986). Morphology of MXT mouse mammary tumors. Correlation with growth characteristics and hormone sensitivity. Eur. J. Cancer Clin. Oncol., 22, 69.
6. Devleeschouwer N., G. Leclercq and J. C. Heuson (1981). Effect of CB 154 (2-Br-Ergocryptine) on MXT mouse mammary tumor growth. I.R.C.S. Med. Sci., 9, 199.
7. EORTC: Breast Cancer Cooperative group (1980). Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur. J. Cancer, 16, 1513.
8. Giambiagi N. and J. R. Pasqualini (1990). Interaction of three monoclonal antibodies with the non activated and activated forms of the estrogen receptor. Endocrinology, 126, 1403.
9. Gotteland M., G. Desauty, J. C. Delarue, L. Liu and E. May (1995). Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues. Mol. Cell. Endocrinol., 112, 1.
10. Halachmi S., E. Marden, G. Martin, H. MacKay, C. Abbondanza and M. Brown (1995). Estrogen receptor-associated proteins: Possible mediators of hormone induced transcription. Science, 264, 1455.
11. Harlow K. W., D. N. Smith, J. A. Katzenellenbogen, G. L. Greene and B. S. Katzenellenbogen (1989). Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. J. Biol. Chem., 264, 17476.
12. Horigome T., F. Ogata, T. S. Golding and K. S. Korach (1988). Estradiol-stimulated proteolytic cleavage of the estrogen receptor in mouse uterus. Endocrinology, 123, 2540.
13. 3H]tamoxifen aziridine. J. Biol. Chem., 258, 3487.
14. Leclercq G., A, Danguy and J. C. Heuson (1982). MXT mouse mammary tumor: effect of ovariectomy on estrogen receptors and histopathology I.R.C.S. Med. Sci., 10, 71.
15. Leclercq G., A. Danguy and J. C. Heuson (1984). MXT mouse mammary tumor: growth inhibition by tamoxifen or estrogen administration. I.R.C.S. Med. Sci., 12. 1984
16. Lemieux P. and S. A. W. Fuqua (1996). The role of the estrogen receptor in tumor progression. J. Steroid Biochem. Molec Biol., 56, 87.
17. Maaroufi Y. and G. Leclercq (1994). Importance of A/B and C domains of the estrogen receptor for its adsorption to hydroxylapatite. J. Steroid Biochem. Molec. Biol., 48, 155.
18. Maaroufi Y., S. Trivedi and G. Leclercq (1995). Major molecular weight heterogeneity of estrogen receptor from breast cancer is not related to neoplasia. Cancer Biochem. Biophys., 15, 67.
19. Michna H., M. R. Schneider, Y. Nishino, E. I. Fathy and M. Eterby (1989). Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies Breast Cancer Res Treat., 14, 275.
20. Migliaccio A., M. Pagano, C. C. J. De Goeij, M. Di Domenico, G. Castoria, M Sluyser and F. Auricchio (1992). Phosphorylation and estradiol binding of estrogen receptor in hormone-dependent and hormone-independent GR mouse mammary tumors. Int. J. Cancer, 51. 733.
21. Miksicek R. J. (1994). Steroid receptor variants and their potential role in cancer. Semin. Cancer Biol., 5, 369.
22. Moncharmont B., G. Ramp, C. C. J. De Goeij and M. Sluyser (1991). Comparison of estrogen receptors in hormone-dependent and hormone-independent Grunder strain mouse
23. Murphy L. C., S. G. Hilsenbeck, H. Dotzlaw and S. A. W. Fuqua (1995). Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer Clin. Cancer Res., 1, 155.
24. OÑate S. A., S. Y. Tsai, M. J. Tsai and B. W. O'Malley (1995). Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science, 270, 1354.
25. Pfeffer U., E. Fearotta, L. Catagnetta and G. Vidali (1993). Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res., 53, 741.
26. Piccart M. J., C. Muquardt, C. Bosman, P. Pirotte, S. Veenstra, F. Grillo and G. Leclercq (1991). Comparison of tritiated estradiol and tamoxifen aziridine for measurement of estrogen receptors in human breast cancer cytosols. J. Natl. Cancer Inst., 83, 1553.
27. Reddin T. W. and A. V. Schally (1983). Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA, 80. 1983.
28. Rees J. C., C. H. Wooge and B. S. Katzenellenbogen (1992). Identification of two cysteines closely positioned in the ligand binding pocket of the human estrogen receptor: Roles in ligand binding and transcriptional activation Mol. Endocrinol., 6, 2160.
29. Rochefort H. (1994). Oestrogens, proteases and breast cancer. From cell lines to clinical applications. Eur. J. Cancer, 30, 1583.
30. Sluyser M. (1995). Mutations in the estrogen receptor gene. Human Mutation, 6, 97.
31. Sluyser M. and J. L. Wittliff (1992). Influence of estrogen receptor variants in mammary carcinomas on the prognostic reliability of the receptor assay. Mol. Cell. Endocrinol., 85, 83.
32. Szende B., G. Srkalovic, K. Groot, K. Lapis and A. V. Schally (1990). Growth inhibition of mouse mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J. Natl. Cancer Inst., 82, 513.
33. Tora L., J. White, C. Brou, D. Tasset, N. Wabster, E. Scheer and P. Chambon (1989). The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell, 59, 477.
34. Trivedi S., M. J. Piccart, C. Muquardt, N. Gilot, S. Hadiy, D. Patel and G. Leclercq (1996). Tamoxifen aziridine labeling of the estrogen receptor-Potential utility in detecting biologically aggressive breast tumors. Breast Cancer Res. Treat., 40, 237.
35. Von Angerer E., J. Prekajac and M. Berger (1985). The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors. Eur. J. Cancer Clin. Oncol., 21. 531.
36. Watson C. S., D. Medina and J. H. Clark (1977). Estrogen characterization in a transplantable mouse mammary tumor. Cancer Res., 37, 3344.
37. Wittliff J L. and E. D. Savlov (1975). Estrogen binding capacity of cytoplasmic forms of the estrogen receptors in human breast cancer. In, W. L. Mc Guire, P. P. Carbone and E. P. Vollmer (Eds.), Estrogen receptors in human breast cancer. Raven Press, New York, Chap. 7. pp. 73-86.
38. Ylikomi T., M. T. Bocquel, M Berry, H Gronemeyer and P. Chambon (1992). Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors, EMBO J., 11, 3681.
39. Zaccheo T. (1985). Antitumor activity of FCE 2136, a new prolactin lowering drug, on the MXT mouse mammary carcinoma. Cancer Lett., 28, 237.
40. Zhang Q. X., A. Borg and S. A. W. Fuqua (1993). An exon 5 deletion variant of the estrogen receptor frequently coexpressed with wild type estrogen receptor in human breast cancer. Cancer Res., 53, 5882.